Brian LaMoreaux

694 total citations
65 papers, 446 citations indexed

About

Brian LaMoreaux is a scholar working on Nephrology, Surgery and Rheumatology. According to data from OpenAlex, Brian LaMoreaux has authored 65 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Nephrology, 30 papers in Surgery and 21 papers in Rheumatology. Recurrent topics in Brian LaMoreaux's work include Gout, Hyperuricemia, Uric Acid (54 papers), Case Reports on Hematomas (20 papers) and Urticaria and Related Conditions (19 papers). Brian LaMoreaux is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (54 papers), Case Reports on Hematomas (20 papers) and Urticaria and Related Conditions (19 papers). Brian LaMoreaux collaborates with scholars based in United States, Switzerland and Australia. Brian LaMoreaux's co-authors include Lissa Padnick‐Silver, Richard J. Johnson, Robert T. Keenan, K. Obermeyer, Michael E. Weinblatt, Megan Francis‐Sedlak, John Tesser, Naomi Schlesinger, Puja Khanna and Robert J. Holt and has published in prestigious journals such as PLoS ONE, Journal of Controlled Release and Journal of the American Society of Nephrology.

In The Last Decade

Brian LaMoreaux

56 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian LaMoreaux United States 13 354 199 179 78 60 65 446
S.-F. Luo China 7 225 0.6× 96 0.5× 98 0.5× 84 1.1× 14 0.2× 16 334
Jeffry D Bieber United States 6 132 0.4× 88 0.4× 150 0.8× 38 0.5× 11 0.2× 6 354
W Taylor New Zealand 7 123 0.3× 83 0.4× 289 1.6× 10 0.1× 8 0.1× 12 385
Adina Welander Sweden 7 145 0.4× 137 0.7× 27 0.2× 19 0.2× 6 0.1× 8 358
Miltiades Kastanakis Greece 8 60 0.2× 219 1.1× 16 0.1× 21 0.3× 17 0.3× 21 316
Yasuaki Kijima Japan 8 69 0.2× 112 0.6× 186 1.0× 60 0.8× 23 0.4× 12 301
Y. Tanter France 11 79 0.2× 61 0.3× 27 0.2× 44 0.6× 5 0.1× 31 283
Heather Gladue United States 8 54 0.2× 60 0.3× 54 0.3× 51 0.7× 8 0.1× 12 384
Roger Sinclair Australia 6 157 0.4× 119 0.6× 31 0.2× 20 0.3× 40 0.7× 8 355
Kimio Takai Japan 11 30 0.1× 156 0.8× 15 0.1× 56 0.7× 7 0.1× 37 424

Countries citing papers authored by Brian LaMoreaux

Since Specialization
Citations

This map shows the geographic impact of Brian LaMoreaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian LaMoreaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian LaMoreaux more than expected).

Fields of papers citing papers by Brian LaMoreaux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian LaMoreaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian LaMoreaux. The network helps show where Brian LaMoreaux may publish in the future.

Co-authorship network of co-authors of Brian LaMoreaux

This figure shows the co-authorship network connecting the top 25 collaborators of Brian LaMoreaux. A scholar is included among the top collaborators of Brian LaMoreaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian LaMoreaux. Brian LaMoreaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Troum, O., Mai Duong, K. Obermeyer, Lissa Padnick‐Silver, & Brian LaMoreaux. (2025). Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. Lara D. Veeken. 64(6). 3328–3333.
2.
Morlock, Robert, Deepan Dalal, Victoria Divino, et al.. (2024). Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis. Rheumatology and Therapy. 12(1). 37–51.
3.
Mudano, Amy S., Fenglong Xie, Jingyi Zhang, et al.. (2024). Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. 76(10). 1361–1370. 2 indexed citations
4.
5.
Stern, Leonard, Richard J. Johnson, Lissa Padnick‐Silver, et al.. (2024). Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review. MDPI (MDPI AG). 2(1). 77–85. 4 indexed citations
6.
7.
Mudano, Amy S., Fenglong Xie, Jingyi Zhang, et al.. (2024). Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. Arthritis Research & Therapy. 26(1). 86–86.
8.
Khanna, Dinesh, et al.. (2023). Economic and Health Care Resource Use Burden of Systemic Sclerosis. ACR Open Rheumatology. 5(12). 677–684. 2 indexed citations
9.
Li, Zhongbo, Limei Shen, Alice Ma, et al.. (2023). Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse. Acta Biomaterialia. 170. 250–259. 12 indexed citations
10.
11.
Padnick‐Silver, Lissa, et al.. (2023). Comparison Between Early-Onset and Common Gout: A Systematic Literature Review. Rheumatology and Therapy. 10(4). 809–823. 6 indexed citations
12.
13.
Padnick‐Silver, Lissa, et al.. (2022). Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study. Rheumatology and Therapy. 9(2). 555–563. 10 indexed citations
14.
Schlesinger, Naomi, Lissa Padnick‐Silver, & Brian LaMoreaux. (2022). Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. BioDrugs. 36(2). 95–103. 15 indexed citations
15.
Abdellatif, Abdul, et al.. (2022). eGFR Changes in Uncontrolled Gout Patients Randomized to Receive Methotrexate or Placebo as Co-Therapy to Pegloticase: MIRROR RCT Findings. Journal of the American Society of Nephrology. 33(11S). 851–851. 1 indexed citations
16.
Saag, Kenneth G., Stephen Ong, K. Obermeyer, et al.. (2022). A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis & Rheumatology. 75(2). 293–304. 35 indexed citations
17.
Padnick‐Silver, Lissa, et al.. (2022). Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout. Rheumatology and Therapy. 9(6). 1549–1558. 4 indexed citations
18.
Francis‐Sedlak, Megan, Brian LaMoreaux, Lissa Padnick‐Silver, Robert J. Holt, & Alfonso E. Bello. (2020). Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatology and Therapy. 8(1). 183–197. 16 indexed citations
19.
Keenan, Robert T., Herbert S. B. Baraf, & Brian LaMoreaux. (2019). Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase. Rheumatology and Therapy. 6(2). 299–304. 19 indexed citations
20.
LaMoreaux, Brian, et al.. (2015). Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Seminars in Arthritis and Rheumatism. 45(4). e10–e12. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S.-F. Luo Breakdown of academic impact, for papers by Jeffry D Bieber Breakdown of academic impact, for papers by W Taylor Breakdown of academic impact, for papers by Adina Welander Breakdown of academic impact, for papers by Miltiades Kastanakis Breakdown of academic impact, for papers by Yasuaki Kijima Breakdown of academic impact, for papers by Y. Tanter Breakdown of academic impact, for papers by Heather Gladue Breakdown of academic impact, for papers by Roger Sinclair Breakdown of academic impact, for papers by Kimio Takai
Rankless by CCL
2026